The real study with relevance to penny stocks like SKTO and

New Post Public Reply Private Reply Replies (0) Message Board
bellsandwhistles Zoofire #35609
The real study with relevance to penny stocks like SKTO and AEGY and derivative boards like these is this landmark UK scientific study:

Study from the UK shows that the science of the brain is a key to understanding the stock market and exploiting it. The human brain is programmed by evolution to discount, reject or underweight unfavorable news, affecting the decision making process. It's called the optimism bias. Understand these inherent biochemical biases as applied to playing the stock market, and fortune may follow.

Researchers Identify Brain Region that Generates Optimism Bias

"Always look on the bright side of life" might seem a simplistic piece of schoolboy philosophy offered by the likes of Monty Python, but they might just have been on to something. A team of University College of London (UCL) neuroscientists and psychologists has discovered that not only does the brain produce an optimism bias for good news, but that such a bias could actually be harmful for our decision-making capabilities. Their results were published on 24 September in the Proceedings of the National Academy of Sciences.

"Humans form beliefs asymmetrically; we tend to discount bad news but embrace good news," the UCL report explains. "This reduced impact of unfavourable information on belief updating may have important societal implications, including the generation of financial market bubbles, ill preparedness in the face of natural disasters, and overly aggressive medical decisions."

The research was led by UCL's Dr Tali Sharot, who specialises in understanding how people form judgments and actions. In a report published in 2007, Sharot discovered that humans tend to expect positive future events, even when there is no evidence to support such expectations -- if it improves your life, or just makes you feel good, you're more likely to believe it will happen despite what the statistics tell you.

Using functional magnetic resonance imaging (fMRI), Sharot identified that a region of the brain called the inferior frontal gyrus (IFG) -- a frontal lobe with both left and right divisions -- was crucial to a person's ability to update their beliefs with new information. Participants in the 2007 study appeared to have a high optimism bias originating from the right IFG, and were worse at modifying their beliefs in the face of undesirable information.

The latest study set out to establish if the formation of a person's beliefs could be altered by selectively manipulating different regions of the IFG. To test the hypotheses that the IFG was involved in the formation of belief, Sharot and her research group used a transcranial magnetic stimulation (TMS) to disrupt the brain functions of three groups of volunteers. One group would have their right IFG disrupted, another their left IFG, and the final group an unrelated control area of their brain.

With the different regions of their brain effectively "shut off" by the TMS, the researchers asked the volunteers to estimate their chances of experiencing 40 different nasty fates, from Alzheimer's disease to robbery. Having recorded the test subject's responses, the researchers presented the participants with the actual likelihood of each of the 40 unpleasant events happening to them, thus modifying their knowledge of the subject. The volunteers were then asked to recalculate their estimates.

The researchers found that participants who received TMS to the control site or right IFG showed the typical good news/bad news effect; they updated their beliefs more when presented with good news relative to bad news. But for the group that had their left IFG disrupted, the results were remarkably different.

This group of volunteers appeared to give equal weight to good or bad news. They would update their opinion if it turned out they were less likely to be robbed (good news), but they would also update their opinion if it turned out they were more likely to suffer from Alzheimer's disease (bad news).

"Our results should not be interpreted as suggesting that the disruption of left IFG function improves learning or decision-making in general," Sharot wrote in the UCL report. "Rather, our study provides an interesting instance of how a selective disruption to a specific brain region may enhance the tendency to integrate negative information into [a person's beliefs] ".

Sharot believes that her work could find clinical applications, targeting the right brain area to encourage people to be more explorative in life, or reduce a person's natural tendency to be anxious or stressed.

The UCL team are yet to speculate on the commercial aspects of such an application. Wired.co.uk is reminded of the Penfield mood organ of Philip K Dick's novel Do androids dream of electric sheep?, an electronic device that could stimulate different emotions in users by simply dialling in a number. Creating or removing an optimism bias could have interesting consequences for people taking on various activities, from assessing stock market moves to deciding on whether to go white water rafting.

http://www.wired.co.uk/news/archive/2012-09/26/optimism-bias

http://www.nature.com/nature/journal/v450/n71...06280.html

SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 397

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 149

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 205

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 606

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 288

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 245

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 223

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 322

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

Care Synergy and RCC Medical Equipment Launch New Partnership

Updated Category News Views 320

Care Synergy and RCC Medical Equipment Form Joint Venture In an exciting development for healthcare services, Care Synergy and RCC Medical Equipment Co. have announced their plans to create a strategic joint venture aimed at improving healthcare delivery in the Colorado Front Range region. This partnership will leverage the strengths of both organizations to provide...

Continue Reading
Revitalizing China's Tourism with High-Tech Cultural Experiences

Updated Category News Views 217

Revitalizing China's Tourism Through High-Tech Cultural Experiences China's tourism industry is undergoing an exciting transformation, fueled by the innovative use of advanced technology paired with its rich cultural heritage. A remarkable example is in Chongqing Municipality, where the city's skyline has become a vibrant showcase of cultural stories, highlighted by...

Continue Reading
Intriguing Insights into United States Steel Options Trades

Updated Category News Views 111

Analyzing Unusual Options Activity in United States Steel Recently, there's been notable market activity where investors with deep pockets are taking a more bearish stance on United States Steel (X). This trend is definitely something for retail traders to pay attention to, especially when navigating the complexities of the stock market. Today's options history unveiled...

Continue Reading
Mesoblast's Operational Highlights and Financial Insights Unveiled

Updated Category News Views 185

Mesoblast Limited's Webcast for Financial Results On a recent occasion, Mesoblast Limited (NASDAQ: MESO; ASX: MSB), a pioneer in allogeneic cellular medicine for inflammatory diseases, announced a webcast to delve into their operational achievements and financial metrics for the half year concluding December 31, 2024. Details of the Webcast Event The engaging webcast is...

Continue Reading
Investors of DXC Technology Prepare for Class Action Lawsuit

Updated Category News Views 77

Investors of DXC Technology Company Take Action In recent months, investors who purchased common stock from DXC Technology Company (NYSE: DXC) have been given a significant opportunity to participate in a class action lawsuit. This situation arises from allegations of securities fraud that are said to have affected many individuals who bought shares during specific key...

Continue Reading